» Articles » PMID: 34070697

Widespread Exaptation of L1 Transposons for Transcription Factor Binding in Breast Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jun 2
PMID 34070697
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

L1 transposons occupy 17% of the human genome and are widely exapted for the regulation of human genes, particularly in breast cancer, where we have previously shown abundant cancer-specific transcription factor (TF) binding sites within the L1PA2 subfamily. In the current study, we performed a comprehensive analysis of TF binding activities in primate-specific L1 subfamilies and identified pervasive exaptation events amongst these evolutionarily related L1 transposons. By motif scanning, we predicted diverse and abundant TF binding potentials within the L1 transposons. We confirmed substantial TF binding activities in the L1 subfamilies using TF binding sites consolidated from an extensive collection of publicly available ChIP-seq datasets. Young L1 subfamilies (L1HS, L1PA2 and L1PA3) contributed abundant TF binding sites in MCF7 cells, primarily via their 5' UTR. This is expected as the L1 5' UTR hosts cis-regulatory elements that are crucial for L1 replication and mobilisation. Interestingly, the ancient L1 subfamilies, where 5' truncation was common, displayed comparable TF binding capacity through their 3' ends, suggesting an alternative exaptation mechanism in L1 transposons that was previously unnoticed. Overall, primate-specific L1 transposons were extensively exapted for TF binding in MCF7 breast cancer cells and are likely prominent genetic players modulating breast cancer transcriptional regulation.

Citing Articles

Transposable elements may enhance antiviral resistance in HIV-1 elite controllers.

Singh M, Leddy S, Iniguez L, Bendall M, Nixon D, Feschotte C Genome Biol. 2025; 26(1):28.

PMID: 39988678 PMC: 11849351. DOI: 10.1186/s13059-025-03484-y.


Prospects for breast cancer immunotherapy using microRNAs and transposable elements as objects.

Mustafin R Explor Target Antitumor Ther. 2024; 5(5):1011-1026.

PMID: 39351441 PMC: 11438560. DOI: 10.37349/etat.2024.00261.


Locus-level L1 DNA methylation profiling reveals the epigenetic and transcriptional interplay between L1s and their integration sites.

Lanciano S, Philippe C, Sarkar A, Pratella D, Domrane C, Doucet A Cell Genom. 2024; 4(2):100498.

PMID: 38309261 PMC: 10879037. DOI: 10.1016/j.xgen.2024.100498.


Comprehensive identification of onco-exaptation events in bladder cancer cell lines revealed L1PA2-SYT1 as a prognosis-relevant event.

Wang Z, Ying Y, Wang M, Chen Q, Wang Y, Yu X iScience. 2023; 26(12):108482.

PMID: 38058305 PMC: 10696462. DOI: 10.1016/j.isci.2023.108482.


Factors Regulating the Activity of LINE1 Retrotransposons.

Protasova M, Andreeva T, Rogaev E Genes (Basel). 2021; 12(10).

PMID: 34680956 PMC: 8535693. DOI: 10.3390/genes12101562.

References
1.
Criscione S, Theodosakis N, Micevic G, Cornish T, Burns K, Neretti N . Genome-wide characterization of human L1 antisense promoter-driven transcripts. BMC Genomics. 2016; 17:463. PMC: 4908685. DOI: 10.1186/s12864-016-2800-5. View

2.
Luan D, Eickbush T . RNA template requirements for target DNA-primed reverse transcription by the R2 retrotransposable element. Mol Cell Biol. 1995; 15(7):3882-91. PMC: 230628. DOI: 10.1128/MCB.15.7.3882. View

3.
JavanMoghadam S, Weihua Z, Hunt K, Keyomarsi K . Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle. 2016; 15(12):1579-90. PMC: 4934046. DOI: 10.1080/15384101.2016.1166327. View

4.
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

5.
Kumar S, Stecher G, Li M, Knyaz C, Tamura K . MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018; 35(6):1547-1549. PMC: 5967553. DOI: 10.1093/molbev/msy096. View